Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VVOS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVivos Therapeutics announces fiscal year 2025 financial results
Filed April 15, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release disclosing full-year 2025 financial performance on April 15, 2026. Actual financial figures and metrics are contained in the attached press release exhibit, not in the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Vivos Therapeutics filed an 8-K to announce its fiscal year 2025 financial results through a press release dated April 15, 2026. This is a routine earnings disclosure under Item 2.02, where companies report material financial information to the public. The 8-K filing itself does not contain the actual financial figures—those details are provided in the attached press release exhibit.
For retail investors, this represents a standard quarterly reporting event. The key information to review would be the attached press release (Exhibit 99.1), which should contain revenue, earnings, cash position, and management commentary on 2025 performance. Investors should compare these results against prior guidance and analyst expectations to assess whether the company met, exceeded, or missed expectations. Watch for the upcoming 10-K annual report, which will provide complete audited financials and detailed business discussion within the next few weeks.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Vivos Therapeutics announced fiscal year 2025 financial results via press release on April 15, 2026.
Added in current filing · verify on EDGAR →
On April 15, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.
The company disclosed its full-year 2025 financial results through a press release. The 8-K itself does not contain the actual financial figures or performance metrics, which are provided in the attached press release exhibit. This is a standard earnings announcement filing under Item 2.02.
Event · Item 9.01 — Financial Statements and Exhibits
Vivos Therapeutics filed an 8-K attaching a press release announcing fiscal year 2025 financial results.
Added in current filing · verify on EDGAR →
Press Release of the Company, dated April 15, 2026, announcing its financial results for the fiscal year ended December 31, 2025.
The company disclosed its full-year 2025 financial results via press release. The 8-K itself contains no financial details; those would be in the attached Exhibit 99.1 press release.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify